Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (7238)	10/24/2002 11:42:44 AM
From: Sidney Street	Respond to of 52153

Biotech Patent Law: This article is no treatise, but it's a decent survey from a couple years ago: signalsmag.com

To: keokalani'nui who wrote (7238)	10/24/2002 8:47:48 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

WE, MLNM have two patent applications directed to proteosome cleavage of the IkappaBalpha and kinase antagonist: 20020086407 23484, a novel human ubiquitin protease 20020151553 Chemokine receptor antagonists and methods of use therefor They bought 341, so it is up to first license contract and what was license to determine do they have intellectual right for proteosome enzyme. This will be under different application assignee search. Miljenko